Pitfalls in the Response Evaluation After Peptide Receptor Radionuclide Therapy With [ 177 Lu-Dota 0 ,Tyr 3 ]Octreotate
Endocrine-Related Cancer - United Kingdom
doi 10.1530/erc-16-0524
Full Text
Open PDFAbstract
Available in full text
Date
May 1, 2017
Authors
Publisher
Bioscientifica